文献速递胸部肿瘤

舒格利单抗对比安慰剂用于中国不可切除III期非小细胞肺癌同步或序贯放化疗后(GEMSTONE-301):随机双盲多中心3期试验中期结果

Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2022-01-14

GEMSTONE-301研究在中国50家医院或学术研究中心纳入381例同步或序贯放化疗后未进展的局部晚期不可切除III期非小细胞肺癌患者,按2:1随机接受舒格利单抗1200 mg或安慰剂静脉注射每3周一次最长24个月。盲态独立中心评审的无进展生存期中位数舒格利单抗组9.0个月(95%CI 8.1-14.1)vs 安慰剂组5.8个月(95%CI 4.2-6.6),分层风险比0.64(95%CI 0.48-0.85),p=0.0026。作者结论认为舒格利单抗可作为有效巩固治疗,需更长随访确认。

要点

  • 同步或序贯放化疗后未进展的III期非小细胞肺癌,舒格利单抗较安慰剂显著延长盲态独立中心评审的无进展生存期。
  • 舒格利单抗组中位无进展生存期9.0个月(95%CI 8.1-14.1)vs 安慰剂组5.8个月(95%CI 4.2-6.6),分层风险比0.64(95%CI 0.48-0.85),p=0.0026。
  • 3级或4级治疗相关不良事件舒格利单抗组22例(9%)vs 安慰剂组7例(6%),治疗相关死亡舒格利单抗组4例(2%)vs 安慰剂组0例。

核心结论

  • 作者认为,在根治性同步或序贯放化疗后,舒格利单抗可作为同步或序贯放化疗后未进展的III期非小细胞肺癌患者的有效巩固治疗,但需更长随访确认该结论。

研究设计与样本

  • GEMSTONE-301是一项随机、双盲、安慰剂对照的3期试验,在中国50家医院或学术研究中心进行。
  • 纳入年龄18岁及以上、ECOG体能状态评分0或1、同步或序贯放化疗后未进展的局部晚期不可切除III期非小细胞肺癌患者。
  • 2018年8月30日至2020年12月30日筛查564例患者,其中381例符合条件,按2:1随机分配接受舒格利单抗1200 mg(n=255)或安慰剂(n=126),静脉注射每3周一次最长24个月。
  • 分层因素为ECOG体能状态评分、既往放化疗方式和总放疗剂量;主要终点为意向治疗人群经盲态独立中心评审的无进展生存期。

主要发现

  • 数据截止2021年3月8日,舒格利单抗组中位随访14.3个月(IQR 6.4-19.4),安慰剂组13.7个月(IQR 7.1-18.4)。
  • 盲态独立中心评审的无进展生存期中位数舒格利单抗组9.0个月(95%CI 8.1-14.1)vs 安慰剂组5.8个月(95%CI 4.2-6.6),分层风险比0.64(95%CI 0.48-0.85),p=0.0026。
  • 3级或4级治疗相关不良事件舒格利单抗组22例(9%)vs 安慰剂组7例(6%),最常见为肺炎或免疫介导性肺炎,舒格利单抗组7例(3%)vs 安慰剂组1例(<1%)。
  • 治疗相关严重不良事件舒格利单抗组38例(15%)vs 安慰剂组12例(10%)。
  • 治疗相关死亡舒格利单抗组4例(2%,其中肺炎2例、肺炎伴免疫介导性肺炎1例、急性肝衰竭1例)vs 安慰剂组0例。

临床怎么用

  • 作者认为,舒格利单抗可作为同步或序贯放化疗后未进展的III期非小细胞肺癌患者的有效巩固治疗,但需更长随访确认。
  • 原文未据此给出其他推荐。

局限性

  • 作者指出需要更长随访来确认该结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A substantial proportion of patients with unresectable stage III non-small-cell lung cancer (NSCLC) cannot either tolerate or access concurrent chemoradiotherapy, so sequential chemoradiotherapy is commonly used. We assessed the efficacy and safety of sugemalimab, an anti-PD-L1 antibody, in patients with stage III NSCLC whose disease had not progressed after concurrent or sequential chemoradiotherapy. METHODS: GEMSTONE-301 is a randomised, double-blind, placebo-controlled, phase 3 trial in patients with locally advanced, unresectable, stage III NSCLC, done at 50 hospitals or academic research centres in China. Eligible patients were aged 18 years or older with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 who had not progressed after concurrent or sequential chemoradiotherapy. We randomly assigned patients (2:1, using an interactive voice-web response system) to receive sugemalimab 1200 mg or matching placebo, intravenously every 3 weeks for up to 24 months. Stratification factors were ECOG performance status, previous chemoradiotherapy, and total radiotherapy dose. The investigators, trial coordination staff, patients, and study sponsor were masked to treatment allocation. The primary endpoint was progression-free survival as assessed by blinded independent central review (BICR) in the intention-to-treat population. Safety was assessed in all participants who received at least one dose of assigned study treatment. The study has completed enrolment and the results of a preplanned analysis of the primary endpoint are reported here. The trial is registered with ClinicalTrials.gov, NCT03728556. FINDINGS: Between Aug 30, 2018 and Dec 30, 2020, we screened 564 patients of whom 381 were eligible. Study treatment was received by all patients randomly assigned to sugemalimab (n=255) and to placebo (n=126). At data cutoff (March 8, 2021), median follow-up was 14·3 months (IQR 6·4-19·4) for patients in the sugemalimab group and 13·7 months (7·1-18·4) for patients in the placebo group. Progression-free survival assessed by BICR was significantly longer with sugemalimab than with placebo (median 9·0 months [95% CI 8·1-14·1] vs 5·8 months [95% CI 4·2-6·6]; stratified hazard ratio 0·64 [95% CI 0·48-0·85], p=0·0026). Grade 3 or 4 treatment-related adverse events occurred in 22 (9%) of 255 patients in the sugemalimab group versus seven (6%) of 126 patients in the placebo group, the most common being pneumonitis or immune-mediated pneumonitis (seven [3%] of 255 patients in the sugemalimab group vs one [<1%] of 126 in the placebo group). Treatment-related serious adverse events occurred in 38 (15%) patients in the sugemalimab group and 12 (10%) in the placebo group. Treatment-related deaths were reported in four (2%) of 255 patients (pneumonia in two patients, pneumonia with immune-mediated pneumonitis in one patient, and acute hepatic failure in one patient) in the sugemalimab group and none in the placebo group. INTERPRETATION: Sugemalimab after definitive concurrent or sequential chemoradiotherapy could be an effective consolidation therapy for patients with stage III NSCLC whose disease has not progressed after sequential or concurrent chemoradiotherapy. Longer follow-up is needed to confirm this conclusion. FUNDING: CStone Pharmaceuticals and the National Key Research and Development Program of China. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Zhou Q, Chen M, Jiang O, et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022. PMID: 35038429. doi:10.1016/S1470-2045(21)00630-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。